EUVIMEDEUVIMED entdecken
Vergleichsstudie

The comparison of paricalcitol and calcitriol effects on pulse wave velocity, osteocalcin, and fetuin‐A in chronic hemodialysis patients

Suleyman Karakose iD, Zeynep Bal, Siren Sezer

Seminars in Dialysis · 2024

DOI: 10.1111/sdi.13167 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Seminars in Dialysis, 2024. Verfasst von Suleyman Karakose und 2 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, University of Health Sciences, Konya City Hospital, Konya, Turkey. Hauptthemen laut MEDLINE: Calcitriol, Ergocalciferols, Vascular Calcification. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Scientific Research Project of Baskent University Faculty of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Vascular calcification is an intervenable factor in the pathophysiology of cardiovascular disease. Treatment‐related factors might worsen the arterial stiffness in chronic hemodialysis patients. The aim of the study is to compare the effects of 1‐year treatment with paricalcitol or calcitriol on pulse wave velocity (PWV), which is an indicator of arterial stiffness and osteocalcin and fetuin‐A levels.

Methods

Seventy‐six hemodialysis patients who had similar PWV1 at the beginning were evaluated after a 1‐year treatment of paricalcitol or calcitriol. PWV2, serum osteocalcin, and fetuin‐A levels were measured at the end of the study.

Results

At the end of the study, PWV2 of paricalcitol group was statistically lower than the calcitriol group. Osteocalcin levels were statistically lower and fetuin‐A levels were statistically higher in the paricalcitol group than the calcitriol group at the end of the study. The number of patients with PWV2 > 7 m/s and using paricalcitol was 16 (39%) but 25 (41%) patients were using calcitriol; the differences were statistically significant.

Conclusions

The long‐term benefits of paricalcitol were superior to the benefits of calcitriol. Paricalcitol has protective effects from vascular calcification in chronic hemodialysis patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CalcitriolErgocalciferolsVascular CalcificationHumansalpha-2-HS-GlycoproteinOsteocalcinParathyroid HormonePulse Wave AnalysisRenal Dialysis

Substanzen

alpha-2-HS-GlycoproteinCalcitriolErgocalciferolsOsteocalcinParathyroid Hormoneparicalcitol

Autor:innen und Institutionen

  • Nephrology Department, University of Health Sciences, Konya City Hospital, Konya, Turkey.
  • Nephrology Department, Baskent University Faculty of Medicine, Ankara, Turkey.

ORCID-Profile: Suleyman Karakose

Förderung

  • Scientific Research Project of Baskent University Faculty of Medicine

Zitieren

APA

Karakose, S., Bal, Z., & Sezer, S. (2024). The comparison of paricalcitol and calcitriol effects on pulse wave velocity, osteocalcin, and fetuin‐A in chronic hemodialysis patients. Seminars in Dialysis. https://doi.org/10.1111/sdi.13167

Vancouver

Karakose S, Bal Z, Sezer S. The comparison of paricalcitol and calcitriol effects on pulse wave velocity, osteocalcin, and fetuin‐A in chronic hemodialysis patients. Seminars in Dialysis. 2024. doi:10.1111/sdi.13167

BibTeX
@article{Karakose2024,
  author = {Karakose, Suleyman and Bal, Zeynep and Sezer, Siren},
  title = {The comparison of paricalcitol and calcitriol effects on pulse wave velocity, osteocalcin, and fetuin‐A in chronic hemodialysis patients},
  journal = {Seminars in Dialysis},
  year = {2024},
  doi = {10.1111/sdi.13167}
}
Kostenlos starten →